11
May

08:00 AM PDT

Clinical Operations

Strategy Meeting West Coast USA 2022

The premier meeting for all West Coast USA Clinical Operations professionals

The Westin St. Francis San Francisco on Union Square

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.

Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across the West Coast in San Francisco, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

See the agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Meet the 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting:

Krista Bradley, MBA, RN

VP & General Manager – Research Nursing & Phlebotomy Solutions – Decentralized Trials IQVIA

Melissa Easy

Vice President, Clinical Technology Offerings IQVIA Technologies

Katy Preciado

Decentralized Clinical Trial Solutions Director IQVIA R&D Solutions

Eli Damron-Rodriguez

Associate Director, RBQM IQVIA Technologies

Gayle Hamilton

Director, RBQM, Digital Trial Management Suite IQVIA Technologies

Sarrah Val

MPH Vice President of Global Sales MD GROUP

Claudia Hesselmann, PhD

Co-founder & CEO ARENSIA

Tatiana Eidus

Director, Corporate Development North America Arensia

Matthew Gordon

VP, Real-World Evidence Strategy Parexel Biotech

Roman Hrynchuk

Chief Operating Officer Sanaclis

Dario Lirio

Senior Director, Product Management Clinical ArisGlobal

Anita Modi

VP, Business Transformation Science 37

Scott Chetham

Co-Founder, CEO Faro Health

Dr. Udayasankar Arulmani

Vice President, Global Clinical Development and Operations Santen Pharmaceuticals

Dr. Uday Arulmani is currently employed in Santen as VP Global Clinical Development and Operations (GCDO). Dr. Uday Arulmani is the clinical trial officer for Santen Pharmaceuticals which is a renowned company specializing in ophthalmic drugs worldwide.
Dr. Uday Arulmani received his medical degree from Madras Medical College, Madras, India. Following his medical degree, he completed his senior residency in Rheumatology and Immunology in Government General Hospital in Madras, India.
In 2000, Dr. Arulmani was awarded a Dutch fellowship to pursue his Master’s in Clinical Epidemiology at the Erasmus Medical Center, Rotterdam, The Netherlands. Following his successful completion of Master’s degree, he continued his PhD in clinical pharmacology.  In addition, Dr. Arulmani received his MBA education from Heriott Watt University, Edinburgh.
Dr. Uday Arulmani has 15 years of pharmaceutical industry experience at major pharmaceutical
companies. He has been serving most recently as a Senior Director, Clinical research in Gilead sciences where he has led the inflammatory bowel disease programs. Previously, he served in different leadership positions at Genentech, Abbvie/Abbott and Novartis Pharma AG (Basel, Switzerland).  Dr. Uday Arulmani has published several peer reviewed articles in international journals and abstracts in major international conferences.  
Dr. Arulmani is passionate in decentralized clinical trials, digital technology and artificial intelligence in clinical development.

Jason Carlton

Vice President, Clinical Operations Jasper Therapeutics

Mr. Carlton joined Jasper Therapeutics in January 2022 as Vice President, Clinical Operations. He has nearly 25 years of industry experience in clinical operations in all phases of clinical development. Before joining Jasper, he was at Genentech where he worked for 3 years as the Therapeutic Area Head, Global Clinical Operations serving the operations teams responsible for all the early development programs within Ophthalmology, CNS, Infectious Disease and Metabolism portfolios. Before that, he was Executive Director, Clinical Operations at Ultragenyx, serving the clinical operations group that successfully led to the company’s first approved therapies for rare and ultra-rare diseases. Before joining Ultragenyx he was an Operations Program Director within Genentech’s late-stage clinical development group for 4 years helping build an ophthalmology franchise that included their first large global phase III registrational program. Prior to joining Genentech, he was a Global Operations Program Leader at Biogen for 4 years leading the TYSABRI clinical operations team and was the global development team lead for the program. He started his career at Merck and led several clinical programs in various therapeutic areas including vaccines, infectious diseases and obesity. Mr. Carlton holds a B.A. in Biology from La Salle University.

Richard Murg

Global Vice President, Business Development Clario

Richard Murg is the Global Vice President of Business Development for the eClinical Solutions Division of Clario. He is responsible for Sales and Marketing and also partners with internal teams to assist in improving products, services and processes that better align with customers’ needs and the long-term growth of Clario eClinical. Richard came to Bioclinica in 2006 as the second salesperson, responsible for the Western United States.  In 2016, became the Vice President of Sales Mid-Markets. During his tenure he was individually responsible for more than $150M in sales and growing annual software sales to greater than $50M.  Due to this success, Richard was engaged by MedNet Solutions to become their Chief Revenue Officer in 2017. There, he increased sales 25% and led them to record bookings in 2018. In 2019, he was recruited back to Bioclinica to recreate his past successes through growing and mentoring the sales team, reposition/expanding the sales tools (marketing) and products to make a significant impact.  Richard is a West Point graduate, has earned an MBA and is a war veteran.

Farah Anwar

Vice President Head of Development Operations Sana Biotechnology

Jenny Chaplin

Vice President, Strategic Operations Bellicum Pharmaceuticals

Ly Kawaguchi

Executive Director, Head of Clinical Outsource and Vendor Governance Curis

Ana Krtolica

Senior Vice President, Preclinical Development Oryn Therapeutics

Suresh Dheerendra

Vice President of Clinical Operations Neuron23 Inc.

Amir Lahav

Digital Healthcare Innovation, Head of Strategic R&D Mitsubishi Tanabe Pharma

Bio: Dr. Amir Lahav is a leading innovator, brain scientist, and an internationally acclaimed advisor in digital health innovation. He has 20 years of experience in the healthcare industry, academic research, clinical trial innovation, and AI-driven technology. Amir’s visionary leadership and changemaker mentality help mobilize the adoption of digital transformation and virtual health. In addition to holding Advisory Board roles at multiple Medtech companies, Amir is also a distinguished consultant to technology startups, pharmaceutical companies, and healthcare organizations including Mitsubishi Tanabe Pharma, Global Alzheimer’s Platform Foundation, Redenlab, and SoloAI to name a few. Formerly, Amir was the Head of Digital Innovation at Pfizer focusing primarily on rare neuromuscular diseases. Prior to pharma, Amir was a professor of pediatrics and neurology faculty at Harvard Medical School where he served as a PI on multiple technology-driven clinical trials.

Prasun Mishra

CEO, Founder / CEO, Founding President r, Agility Pharmaceuticals / American Association for Precision Medicine (AAPM)

First name	Last name	Job title	Company name	Photo URL	Bio Position
Krista	Bradley, MBA,	VP & General Manager – Research Nursing & Phlebotomy Solutions – Decentralized Trials	IQVIA	https://proventainternational.com/wp-content/uploads/2021/10/krista-bradley.jpeg
Melissa	Easy	Vice President, Clinical Technology Offerings	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2021/02/Melissa-easy-2021-e1634632271290.jpg	Melissa Easy is Vice-President of R&D Technologies at IQVIA, responsible for the strategy, delivery and development of technology portfolio and technology-enabled services that improve clinical trial delivery for IQVIA and customer clinical trials more efficiently. She believes we must take advantage of orchestrated technology to bring patients, sites, and sponsors together in a concerted effort to save time, money, and lives. Melissa is a frequent speaker in the industry and has received many awards including PharmaVoice 100 and most recently being named an HBA Luminary.
Katy	Preciado	Decentralized Clinical Trial Solutions Director	IQVIA R&D Solutions	https://proventainternational.com/wp-content/uploads/2021/10/Katy-Preciado.jpg	Katy Preciado is the Decentralized Clinical Trials Solutions Director at IQVIA, where she managed DCT trials across phases I-IV and indications, including dermatology, infectious diseases/vaccines, oncology and CNS. With over 12 years of experience in the clinical research industry, Katy was a founding member of one of the first US DCT companies. Katy joined IQVIA in 2019, and soon after took over an extensive portfolio of COVID treatment trials and COVID-mitigation trials utilizing decentralized capabilities. Katy received her Master of Public Health in research epidemiology from Loma Linda University.
Eli	Damron-Rodriguez	Associate Director, RBQM	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/04/Eli-Damron-Rodriguez.jpg
Gayle	Hamilton	Director, RBQM, Digital Trial Management Suite	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/04/Gayle-Hamilton-New-1.jpg	Gayle Hamilton is an experienced Risk-Based Monitoring project advisor and project lead with a strong background in clinical operations and project management. She has supported study trial teams and IT development in RBQM implementation across all phases and therapeutic areas, driving the development of processes, tools, and systems. Gayle is also experienced in assuring high-quality business performance of clinical operations within global projects.
Sarrah	Val	MPH Vice President of Global Sales	MD GROUP	https://proventainternational.com/wp-content/uploads/2022/02/Sarrah-Val.jpg	Earned her Masters in Public Health from the University of Southern California after completing a dual degree in Integrative Physiology and Mathematics from the University of Colorado, Boulder. She is driven by her love for patient care, and invests her industry efforts into making clinical trials more accessible, equitable, and patient-focused. With prior experience in Medical Affairs and as a Director of Clinical Operations, she has led clinical trials from protocol design through FDA approval, driven physician education initiatives, and facilitated post-market and investigator grant research.
Claudia	Hesselmann, PhD	Co-founder & CEO	ARENSIA	https://proventainternational.com/wp-content/uploads/2020/01/Claudia-Hesselmann-Arensia-Headshot-e1584469734743.png	Claudia Hesselmann, PhD, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.
Tatiana	Eidus	Director, Corporate Development North America	Arensia	https://proventainternational.com/wp-content/uploads/2020/05/Tatiana-Eidus.jpg	Tatiana Eidus received her Master’s Degree in Biophysics from Moscow State University. Entering the industry more than a decade ago, Tatiana has accumulated wide expertise in all the operational aspects of initiating and managing Phase I-III trials across Europe and US. Prior to joining ARENSIA Exploratory Medicine, Tatiana worked for GSK and Merck. Primarily focused on early-stage exploratory programs, she conducted trials in various disease areas. In her current role as Director Corporate Development, Tatiana supports ARENSIA’s partners in the US, supervising cross-functional coordination throughout study planning, start-up and execution.
Matthew	Gordon	VP, Real-World Evidence Strategy	Parexel Biotech	https://proventainternational.com/wp-content/uploads/2022/03/Matthew-Gordon.jpg
Roman	Hrynchuk	Chief Operating Officer	Sanaclis	https://proventainternational.com/wp-content/uploads/2021/02/Roman-Hrynchuk-New.jpg	Roman leads key company business by providing strategic direction and day-to-day oversight. With 15 years of experience in pharmaceutical business, Roman leverages a profound and deep knowledge of clinical research and a passion for operations, to continuously improve the company’s performance, whilst retaining compliance with regulatory requirements and best practices. Additionally, Roman is responsible for the regular control and management of SanaClis’s operational departments such as, Clinical Operations, Clinical Trial Supply Chain, Data Management, Pharmacovigilance/Medical Affairs and Sourcing. Further to Roman’s oversight of the aforementioned internal departments within SanaClis, Roman also plays a vital role in ensuring the implementation and continuous development of key operational strategies/objectives and thereby accomplishing the company’s high standards and corporate goals.
Dario	Lirio	Senior Director, Product Management Clinical	ArisGlobal	https://proventainternational.com/wp-content/uploads/2021/11/dario-lirio.jpg	Dario Lirio is responsible for the ArisGlobal Clinical product strategy roadmap and the growth of the domain. Dario has nearly 18 years of experience with secure content sharing. Prior to ArisGlobal, Dario worked at Intralinks and Veeva, working on Study Start-up, Safety Document Distribution, and eTMF.
Anita	Modi	VP, Business Transformation	Science 37	https://proventainternational.com/wp-content/uploads/2022/05/Anita-Modi.jpg
Scott	Chetham	Co-Founder, CEO	Faro Health	https://proventainternational.com/wp-content/uploads/2022/03/Scott-Chetham.jpg	Scott Chetham Ph.D. is an experienced healthcare entrepreneur who is currently the CEO and co-founder of Faro Health. Scott leads the strategy for the Faro Health platform, which is designed to power clinical development by connecting data to decision making in a fundamentally new way. Previously, he was the Head of Clinical Research Operations and Data Management at Verily Life Sciences, formerly known as Google Life Sciences. This multifaceted strategic and operational role involved leading the clinical strategy, clinical teams, process development and operations for all clinical projects of the company, including Google and Google[x]. Scott has also served as a Venture Partner at Versant Ventures, CTO and Co-founder of Intersection Medical (sold to ImpediMed), and VP Clinical Affairs (ImpediMed). In these latter two roles he was responsible for clinical research strategy and operations.
Dr.	Udayasankar Arulmani	Vice President, Global Clinical Development and Operations	Santen Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/10/Udayasankar-Arulmani-Santen-Santen.jpg	Dr. Uday Arulmani is currently employed in Santen as VP Global Clinical Development and Operations (GCDO). Dr. Uday Arulmani is the clinical trial officer for Santen Pharmaceuticals which is a renowned company specializing in ophthalmic drugs worldwide. Dr. Uday Arulmani received his medical degree from Madras Medical College, Madras, India. Following his medical degree, he completed his senior residency in Rheumatology and Immunology in Government General Hospital in Madras, India. In 2000, Dr. Arulmani was awarded a Dutch fellowship to pursue his Master’s in Clinical Epidemiology at the Erasmus Medical Center, Rotterdam, The Netherlands. Following his successful completion of Master’s degree, he continued his PhD in clinical pharmacology. In addition, Dr. Arulmani received his MBA education from Heriott Watt University, Edinburgh. Dr. Uday Arulmani has 15 years of pharmaceutical industry experience at major pharmaceutical companies. He has been serving most recently as a Senior Director, Clinical research in Gilead sciences where he has led the inflammatory bowel disease programs. Previously, he served in different leadership positions at Genentech, Abbvie/Abbott and Novartis Pharma AG (Basel, Switzerland). Dr. Uday Arulmani has published several peer reviewed articles in international journals and abstracts in major international conferences. Dr. Arulmani is passionate in decentralized clinical trials, digital technology and artificial intelligence in clinical development.
Jason	Carlton	Vice President, Clinical Operations	Jasper Therapeutics	https://proventainternational.com/wp-content/uploads/2022/03/Jason-Carlton-Jasper.jpg	Mr. Carlton joined Jasper Therapeutics in January 2022 as Vice President, Clinical Operations. He has nearly 25 years of industry experience in clinical operations in all phases of clinical development. Before joining Jasper, he was at Genentech where he worked for 3 years as the Therapeutic Area Head, Global Clinical Operations serving the operations teams responsible for all the early development programs within Ophthalmology, CNS, Infectious Disease and Metabolism portfolios. Before that, he was Executive Director, Clinical Operations at Ultragenyx, serving the clinical operations group that successfully led to the company’s first approved therapies for rare and ultra-rare diseases. Before joining Ultragenyx he was an Operations Program Director within Genentech’s late-stage clinical development group for 4 years helping build an ophthalmology franchise that included their first large global phase III registrational program. Prior to joining Genentech, he was a Global Operations Program Leader at Biogen for 4 years leading the TYSABRI clinical operations team and was the global development team lead for the program. He started his career at Merck and led several clinical programs in various therapeutic areas including vaccines, infectious diseases and obesity. Mr. Carlton holds a B.A. in Biology from La Salle University.
Richard	Murg	Global Vice President, Business Development	Clario	https://proventainternational.com/wp-content/uploads/2022/03/Richard-Murg.jpg	Richard Murg is the Global Vice President of Business Development for the eClinical Solutions Division of Clario. He is responsible for Sales and Marketing and also partners with internal teams to assist in improving products, services and processes that better align with customers’ needs and the long-term growth of Clario eClinical. Richard came to Bioclinica in 2006 as the second salesperson, responsible for the Western United States. In 2016, became the Vice President of Sales Mid-Markets. During his tenure he was individually responsible for more than $150M in sales and growing annual software sales to greater than $50M. Due to this success, Richard was engaged by MedNet Solutions to become their Chief Revenue Officer in 2017. There, he increased sales 25% and led them to record bookings in 2018. In 2019, he was recruited back to Bioclinica to recreate his past successes through growing and mentoring the sales team, reposition/expanding the sales tools (marketing) and products to make a significant impact. Richard is a West Point graduate, has earned an MBA and is a war veteran.
Farah	Anwar	Vice President Head of Development Operations	Sana Biotechnology	https://proventainternational.com/wp-content/uploads/2021/10/Farah-Anwar.jpg
Jenny	Chaplin	Vice President, Strategic Operations	Bellicum Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/10/jenny-chaplin.jpeg	Jenny Chaplin is Vice President, Strategic Operations, at Bellicum Pharmaceuticals. She is an accomplished, results-driven, and versatile drug development professional, with a strong track record of organization excellence and translating strategy into execution. She has delivered multiple projects on target, managed challenging global alliances, and successfully taken on diverse functional leadership roles. At Bellicum she is currently responsible for corporate operations, project management, and clinical operations for cell therapy programs. Prior to joining Bellicum in 2018, she was Director, Project Management at Pfizer, where she led cross-functional teams in early stage development of oncology therapies. She held roles of increasing responsibility in program management at Vical after transitioning from an early career in research in the US and South Africa. Jenny graduated from the University of the Witwatersrand with a B.Sc (Hons).
Ly	Kawaguchi	Executive Director, Head of Clinical Outsource and Vendor Governance	Curis	https://proventainternational.com/wp-content/uploads/2021/11/Ly-Kawaguchi-MyoKardia.jpg	Ly has more than 25 years of experience in the biotech/pharmaceutical industry in large, medium, and small companies across all phases of research and development. Ly has extensive expertise in leading Clinical Operations, Clinical and R&D outsource and contracts management, CRO and vendor oversight, and quality/compliance. She has built and led multiple groups at Genentech, Allegan, Ultragenyx, MyoKardia, and most recently at Curis. Ly has a B.S in Environmental Toxicology.
Ana	Krtolica	Senior Vice President, Preclinical Development	Oryn Therapeutics	https://proventainternational.com/wp-content/uploads/2022/01/anakrtolica.jpg	Ana completed PhD at University of Rochester. As a postdoc and then, scientist at LBNL and UCSF she explored the influence of microenvironment on carcinogenesis and stem cell phenotype. Ana co-founded and led StemLifeLine, a startup focusing on cell therapy and development of the cancer drug discovery platform. After joining Omniox, Ana developed programs in oncology, ischemic stroke and critical care bringing its technology from early discovery to clinic. She currently leads translational and new indication efforts at Retrotope. Ana received >$5M in grants and serves on NIH Review Boards. She authored multiple patent applications and published >30 research papers.
Suresh	Dheerendra	Vice President of Clinical Operations	Neuron23 Inc.	https://proventainternational.com/wp-content/uploads/2021/10/suresh-dheerendra.jpeg	Suresh Dheerendra is the Vice President of Clinical Operations at Neuron23, an early stage biotechnology company focused on developing personalized medicines for genetically defined neurological and immunological diseases. Prior to joining Neuron23, Suresh was a Clinical Program Director at Genentech in the Research and Early Development (gRED) group. Suresh’s career spans over 20+ years in various roles within Clinical Operations, including: Lundbeck, Takeda Pharmaceuticals, and Abbott/Abbvie. Suresh holds a BS degree in Biology, (Plant Genetics), from Northern Illinois University and a MS degree in Health Care Administration from DePaul University.
Amir	Lahav	Digital Healthcare Innovation, Head of Strategic R&D	Mitsubishi Tanabe Pharma	https://proventainternational.com/wp-content/uploads/2022/03/Amir-Lhav.jpg	Bio: Dr. Amir Lahav is a leading innovator, brain scientist, and an internationally acclaimed advisor in digital health innovation. He has 20 years of experience in the healthcare industry, academic research, clinical trial innovation, and AI-driven technology. Amir’s visionary leadership and changemaker mentality help mobilize the adoption of digital transformation and virtual health. In addition to holding Advisory Board roles at multiple Medtech companies, Amir is also a distinguished consultant to technology startups, pharmaceutical companies, and healthcare organizations including Mitsubishi Tanabe Pharma, Global Alzheimer’s Platform Foundation, Redenlab, and SoloAI to name a few. Formerly, Amir was the Head of Digital Innovation at Pfizer focusing primarily on rare neuromuscular diseases. Prior to pharma, Amir was a professor of pediatrics and neurology faculty at Harvard Medical School where he served as a PI on multiple technology-driven clinical trials.
Prasun	Mishra	CEO, Founder / CEO, Founding President	r, Agility Pharmaceuticals / American Association for Precision Medicine (AAPM)	https://proventainternational.com/wp-content/uploads/2020/05/Prasun-Mishra-Pic-Prasun-Mishra-e1589209319911.jpeg	Dr. Prasun Mishra is an investor, co-founder and board member of a few US based corporations. He leads the research efforts focused on preventing and curing COVID-19, cancer, and other chronic diseases. He has numerous publications, patents and several drugs in clinical trials to his credit. He is a recipient of over 40 prestigious awards and honors, including a recent recognition by Thrive Global and Authority Magazine as a ‘Social Impact Hero’. Due to his unique perspective and selfless service, he is a highly respected and sought-after mentor to many.

Krista Bradley, MBA, RN, Melissa Easy, Katy Preciado, Eli Damron-Rodriguez, Gayle Hamilton, Sarrah Val, Claudia Hesselmann, PhD, Tatiana Eidus, Matthew Gordon, Roman Hrynchuk, Dario Lirio, Anita Modi, Scott Chetham, Dr. Udayasankar Arulmani, Jason Carlton, Richard Murg, Farah Anwar, Jenny Chaplin, Ly Kawaguchi, Ana Krtolica, Suresh Dheerendra, Amir Lahav, Prasun Mishra

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials San Francisco

Clinical Operations

Strategy Meeting West Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >The Westin St. Francis San Francisco on Union Square

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Become an official strategy meeting partner

Press play to hear what your colleagues had to say…

See the agenda and facilitator line-up

Meet the 2022 Facilitators

Krista Bradley, MBA, RN

Melissa Easy

Katy Preciado

Eli Damron-Rodriguez

Gayle Hamilton

Sarrah Val

Claudia Hesselmann, PhD

Tatiana Eidus

Matthew Gordon

Roman Hrynchuk

Dario Lirio

Anita Modi

Scott Chetham

Dr. Udayasankar Arulmani

Jason Carlton

Richard Murg

Farah Anwar

Jenny Chaplin

Ly Kawaguchi

Ana Krtolica

Suresh Dheerendra

Amir Lahav

Prasun Mishra

Lead Sponsor

Our 2022 Thought Leader

Our 2022 Co-hosts Sponsors

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

The Westin St. Francis San Francisco on Union Square